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Dear Editors,
We thank Dr. Paul Hutson for his thorough commentary [1]
on our recent article entitled ‘Enzalutamide: a step towards
pharmacokinetic-based dosing in men with metastatic
castration-resistant prostate cancer’ [2]. We would like to
provide an important correction to Dr. Hutson’s commen-
tary, regarding the following statements:
Gibbons et al. do not report the renal clearance or the
effect of renal failure on the clearance of enzalu-
tamide or its active N-desmethyl metabolite, and to
date no other reports of enzalutamide renal clearance
are available to guide dosing. The mass-balance
studies in the present study demonstrate that
approximately 60 % of the dose was recovered in the
urine, suggesting that dosing of the drug may need to
be reduced in patients with kidney dysfunction.
While not emphasized, the article does describe renal
clearance on page 1050 (paragraph 2):
The major route of excretion of 14C-radioactivity was
urine (71.0 % of dose), primarily as metabolites. The
remainder of the radioactivity was excreted in feces
(13.6 % of dose). Based on LC–MS/MS analysis, the
main component in urine was the carboxylic acid
metabolite, which accounted for 62.7 % of the dose.
A trace amount of unchanged parent enzalutamide
was excreted in urine. N-Desmethyl enzalutamide
was too low to quantitate in urine by LC–MS/MS.
Based on this information, renal excretion is a minor
elimination pathway for unchanged parent enzalu-
tamide and N-desmethyl enzalutamide.
As indicated in this excerpt, 62.7 % of the dose was
recovered in urine as the inactive carboxylic acid
metabolite, and the remainder was additional minor
metabolites; enzalutamide and N-desmethyl enzalutamide
(active metabolite) were present in urine at only trace
amounts. These data indicate that renal excretion is a minor
elimination pathway for unchanged parent enzalutamide
and N-desmethyl enzalutamide. Further details are captured
in the US prescribing information for XTANDI (enzalu-
tamide) capsules (product label), which states the
following:
A dedicated renal impairment trial for XTANDI has
not been conducted. Based on the population phar-
macokinetic analysis using data from clinical trials in
patients with metastatic CRPC and healthy volun-
teers, no significant difference in enzalutamide
clearance was observed in patients with pre-existing
mild to moderate renal impairment [30 mL/
min B creatinine clearance (CrCL) B 89 mL/min]
compared to patients and volunteers with baseline
normal renal function (CrCL C90 mL/min). No ini-
tial dosage adjustment is necessary for patients with
mild to moderate renal impairment. Severe renal
impairment (CrCL\30 mL/min) and end-stage renal
disease have not been assessed [see Clinical Phar-
macology (12.3)].
In summary, data presented in our original research
article [2], as well as results in the XTANDI product
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label, indicate that starting dose reductions are not required
in patients with mild to moderate renal impairment. There
are no data to assess the effects of severe renal impairment
(CrCL\30 mL/min). As Dr. Hutson’s commentary mis-
states dosing recommendations for XTANDI, we request
that you kindly publish a supplementary response to Dr.
Hutson’s commentary in Clinical Pharmacokinetics.
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